Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is slated to report third-quarter 2025 results on Nov. 5, before the opening bell.
SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...
Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.34 per share a year ago. These ...
TipRanks on MSN
Roche Exercises Option with Recursion Pharmaceuticals
An announcement from Recursion Pharmaceuticals ( ($RXRX) ) is now available. On October 29, 2025, Recursion Pharmaceuticals announced that Roche ...
Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMTSalt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage ...
Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback